AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 1 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Enclosing adenovirus-based recombinant gene therapies in alginate microspheres could be one way to eliminate undesirable immune response, according to a study performed at Purdue University in West Lafayette, Indiana.
"Preexisting immunity against adenoviruses may compromise the efficacy of adenoviral vectors for vaccination and gene therapy," G. Sailaja and colleagues advised in the December 2002 edition of Gene Therapy.
The investigators suggested encapsulation might overcome the problem of preexisting immune response after studying alginate microparticles containing adenoviruses encoding for beta-galactosidase (LacZ) in several laboratory animals.
To examine encapsulation efficacy, Sailaja and fellow investigators first inoculated mice with human adenovirus type 5 (HAd5) to generate antibodies, and then challenged the animals with encapsulated or nonencapsulated vectors.
HAd5 antibody-primed animals exhibited lower LacZ expression after inoculation with nonencapsulated vector than did nonprimed animals who received the same vaccination. This suggested heightened immune system activity in the primed animals, according to Sailaja and coauthors (Encapsulation of recombinant adenovirus into alginate microspheres ...
Source: HighBeam Research, Adenovirus encapsulation curbs immune response problems of gene...